[go: up one dir, main page]

WO2010008719A3 - Formulations pharmaceutiques orales d’antagonistes de vla-4 - Google Patents

Formulations pharmaceutiques orales d’antagonistes de vla-4 Download PDF

Info

Publication number
WO2010008719A3
WO2010008719A3 PCT/US2009/047353 US2009047353W WO2010008719A3 WO 2010008719 A3 WO2010008719 A3 WO 2010008719A3 US 2009047353 W US2009047353 W US 2009047353W WO 2010008719 A3 WO2010008719 A3 WO 2010008719A3
Authority
WO
WIPO (PCT)
Prior art keywords
vla
pharmaceutical formulations
oral pharmaceutical
antagonists
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/047353
Other languages
English (en)
Other versions
WO2010008719A9 (fr
WO2010008719A2 (fr
Inventor
David Harris
Ramya Kumbale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of WO2010008719A2 publication Critical patent/WO2010008719A2/fr
Publication of WO2010008719A3 publication Critical patent/WO2010008719A3/fr
Publication of WO2010008719A9 publication Critical patent/WO2010008719A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques orales comprenant un antagonistes de VLA-4 et un tensioactif. Dans un mode de réalisation préféré, l’antagoniste de VLA-4 est le sel monosodique d’acide (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-méthyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(4-méthylphényl)propanoïque. La présente invention concerne en outre des procédés pour traiter et/ou prévenir et/ou inhiber la progression d’une maladie inflammatoire utilisant de telles formulations pharmaceutiques.
PCT/US2009/047353 2008-06-16 2009-06-15 Formulations pharmaceutiques orales d’antagonistes de vla-4 Ceased WO2010008719A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6185708P 2008-06-16 2008-06-16
US61/061,857 2008-06-16

Publications (3)

Publication Number Publication Date
WO2010008719A2 WO2010008719A2 (fr) 2010-01-21
WO2010008719A3 true WO2010008719A3 (fr) 2010-03-11
WO2010008719A9 WO2010008719A9 (fr) 2010-07-01

Family

ID=41395474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/047353 Ceased WO2010008719A2 (fr) 2008-06-16 2009-06-15 Formulations pharmaceutiques orales d’antagonistes de vla-4

Country Status (1)

Country Link
WO (1) WO2010008719A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019246455A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal par un inhibiteur de l'intégrine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761266A1 (fr) * 1997-03-28 1998-10-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
US6238695B1 (en) * 1998-04-07 2001-05-29 Dupont Pharmaceuticals Company Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
WO2004044046A2 (fr) * 2002-11-08 2004-05-27 Encysive Pharmaceuticals Produits de combinaison comprenant des derives d'acide carboxylique inhibant la liaison des integrines a leurs recepteurs et autres composes therapeutiques
US20050003001A1 (en) * 2001-11-07 2005-01-06 Hisami Yamaguchi Method for improving dissolution of poorly dispersible medicaments

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761266A1 (fr) * 1997-03-28 1998-10-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
US6238695B1 (en) * 1998-04-07 2001-05-29 Dupont Pharmaceuticals Company Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
US20050003001A1 (en) * 2001-11-07 2005-01-06 Hisami Yamaguchi Method for improving dissolution of poorly dispersible medicaments
WO2004044046A2 (fr) * 2002-11-08 2004-05-27 Encysive Pharmaceuticals Produits de combinaison comprenant des derives d'acide carboxylique inhibant la liaison des integrines a leurs recepteurs et autres composes therapeutiques

Also Published As

Publication number Publication date
WO2010008719A9 (fr) 2010-07-01
WO2010008719A2 (fr) 2010-01-21

Similar Documents

Publication Publication Date Title
WO2007022535A3 (fr) Promedicaments d'agents actifs
UA96126C2 (ru) Соединение для ингибирования активности rho киназы, фармацевтическая композиция, которая содержит такое соединение, и способ ингибирования активности rho киназы
WO2008057802A3 (fr) Compositions comprenant des agents d'inhibition de la pompe à protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procédés d'utilisation
WO2010032875A3 (fr) Composés de carboxamide hétérocycliques
WO2007019251A3 (fr) Inhibiteurs de la sphingosine kinase et leurs methodes d'utilisation
CL2007002499A1 (es) Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
WO2007120689A3 (fr) Procédés d'utilisation du récepteur gpr119 pour identifier des composés utiles pour augmenter la masse osseuse chez un individu
IL218976A0 (en) (2s,3r) - n - (2 - ((3 - pyridinyl) methyl) - 1 - azabicyclo [2.2.2] oct - 3 - yl) benzofuran - 2 - carboxamide, novel salt forms, and methods of use thereof
WO2005117870A3 (fr) Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique
WO2010078324A3 (fr) Compositions pour animaux de compagnie comprenant de l'acide lipoïque et leurs procédés d'utilisation
WO2009117421A3 (fr) Modulateurs hétérocycliques de gpr119 pour le traitement d’une maladie
WO2007089548A3 (fr) Composés et procédés de modulation du trafic de protéines
PL2103214T3 (pl) Zastosowanie związków chinoliny, lub ich soli, jako substancji czynnych w środkach do traktowania gleby lub zaprawiania nasion oraz sposób kontrolowania chorób roślin
NO20083836L (no) N-hydroksyakrylamidforbindelser
ZA200801854B (en) Method of preparing esomeprazole and salts thereof
WO2011009039A3 (fr) Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie
WO2007084221A3 (fr) Procédés et appareil pour l'identification de matière dans des données de visualisation
WO2009102443A3 (fr) Formulation d'acide octanoïque et procédés de traitement les employant
WO2009100275A3 (fr) Compositions et dispositifs
WO2007095250A3 (fr) Compositions et procedes pour inhiber une lesion du nerf optique
MX2013003863A (es) Metodo para la preparacion de (3s,3s')4,4'-disulfandilbis(acido 3-aminobutano 1-sulfonico).
IL213136A0 (en) Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
WO2010008719A3 (fr) Formulations pharmaceutiques orales d’antagonistes de vla-4
ITFI20050041A1 (it) Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono
MX2009005247A (es) Metodos para mejorar la biodisponibilidad de un inhibidor de renina.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09741501

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09741501

Country of ref document: EP

Kind code of ref document: A2